GlassScriptPhysician profile
Catherine A Le
NPI 1932144656
$3,015.93
in general payments reported to CMS, 2019-2025
19 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $279 · 2023: $620 · 2024: $659 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,737.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.41 | 2022-2025 | |
| Janssen Biotech, INC. | $332.58 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $292.90 | 2022-2024 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $271.57 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.67 | 2022-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $221.56 | 2024-2025 | Rezdiffra |
| Boston Scientific Corporation | $187.15 | 2024 | Exalt Model D |
| Neurocrine Biosciences, INC. | $131.87 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $124.41 | 2025 | Dupixent |
| Ardelyx, INC. | $96.66 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $80.64 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $60.14 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $54.43 | 2025 | Zenpep, Vowst |
| Novo Nordisk INC | $42.44 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $35.38 | 2025 | Rebyota |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.23 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $33.80 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $27.90 | 2024 | Zerbaxa, Dificid, Recarbrio |
| Lilly USA, LLC | $20.19 | 2025 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.